Caisse DE Depot ET Placement DU Quebec reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,700 shares of the company’s stock after selling 1,000 shares during the period. Caisse DE Depot ET Placement DU Quebec’s holdings in IDEXX Laboratories were worth $891,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of IDXX. Raymond James Financial Services Advisors Inc. boosted its stake in IDEXX Laboratories by 67.1% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 9,985 shares of the company’s stock valued at $1,553,000 after acquiring an additional 4,008 shares during the period. Victory Capital Management Inc. boosted its position in shares of IDEXX Laboratories by 5.3% during the third quarter. Victory Capital Management Inc. now owns 10,440 shares of the company’s stock worth $1,623,000 after buying an additional 521 shares during the period. BNP Paribas Arbitrage SA boosted its position in shares of IDEXX Laboratories by 80.1% during the third quarter. BNP Paribas Arbitrage SA now owns 50,090 shares of the company’s stock worth $7,788,000 after buying an additional 22,277 shares during the period. Sei Investments Co. boosted its position in shares of IDEXX Laboratories by 10.4% during the third quarter. Sei Investments Co. now owns 43,446 shares of the company’s stock worth $6,756,000 after buying an additional 4,102 shares during the period. Finally, New York State Common Retirement Fund boosted its position in shares of IDEXX Laboratories by 5.9% during the third quarter. New York State Common Retirement Fund now owns 252,700 shares of the company’s stock worth $39,292,000 after buying an additional 14,000 shares during the period. Institutional investors own 87.09% of the company’s stock.
In related news, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $165.15, for a total transaction of $2,972,700.00. Following the sale, the chief executive officer now owns 1,077,112 shares of the company’s stock, valued at $177,885,046.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jonathan W. Ayers sold 2,160 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $167.03, for a total value of $360,784.80. Following the sale, the chief executive officer now directly owns 1,077,112 shares in the company, valued at approximately $179,910,017.36. The disclosure for this sale can be found here. In the last three months, insiders have sold 91,736 shares of company stock worth $16,193,502. 2.77% of the stock is owned by corporate insiders.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $204.73 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.80 and a debt-to-equity ratio of -11.26. The stock has a market capitalization of $17,736.46, a P/E ratio of 69.64, a PEG ratio of 2.50 and a beta of 0.58. IDEXX Laboratories, Inc. has a 52-week low of $146.09 and a 52-week high of $207.14.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, February 1st. The company reported $0.77 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm had revenue of $506.00 million for the quarter, compared to analysts’ expectations of $490.51 million. During the same quarter in the previous year, the company earned $0.58 earnings per share. The firm’s quarterly revenue was up 14.2% compared to the same quarter last year. research analysts anticipate that IDEXX Laboratories, Inc. will post 4.09 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by Week Herald and is the property of of Week Herald. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://weekherald.com/2018/03/17/caisse-de-depot-et-placement-du-quebec-decreases-holdings-in-idexx-laboratories-inc-idxx.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.